First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease-Reference-Cited by-同舟云学术

First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease

Published:2024-05-15 Issue:11 Volume:15 Page:2099-2111
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Santini Alan¹,Tassinari Elisa¹,Poeta Eleonora²,Loi Manuela³,Ciani Elisabetta³,Trazzi Stefania³,Piccarducci Rebecca⁴,Daniele Simona⁴,Martini Claudia⁴^ORCID,Pagliarani Barbara¹,Tarozzi Andrea¹^ORCID,Bersani Matteo⁵,Spyrakis Francesca⁵^ORCID,Danková Daniela⁶^ORCID,Olsen Christian A.⁶^ORCID,Soldati Roberto¹,Tumiatti Vincenzo¹,Montanari Serena¹,De Simone Angela⁵,Milelli Andrea¹^ORCID

Affiliation:

1. Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d’Augusto 237, 47921 Rimini, Italy

2. Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy

3. Department of Biomedical and Neuromotor Science, Alma Mater Studiorum-University of Bologna, Piazza di Porta S. Donato, 2, 40126 Bologna, Italy

4. Department of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy

5. Department of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy

6. Center for Biopharmaceuticals and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark

Funder

European Commission

Universit? degli Studi di Torino

Danmarks Frie Forskningsfond

Universit? di Bologna

Ministero dell'Universit? e della Ricerca

Universit? di Pisa

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.4c00061

Reference49 articles.

1. Alzheimer's disease drug development pipeline: 2022

2. Alzheimer’s Disease, the “One-Molecule, One-Target” Paradigm, and the Multitarget Directed Ligand Approach

3. Harnessing Polypharmacology with Medicinal Chemistry

4. Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer’s Disease

5. Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?